Tag: cd-19 antibody market key players

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Are The Market Size Estimates For The CD-19 Antibody Market?

Recent years have seen a robust growth in the size of the CD-19 antibody market. The market, which will expand from $1.75 billion in 2024 to $1.89 billion in 2025, is anticipated to have a compound annual growth rate of 8.3%. The growth during the historical period is linked to factors such as the rising incidence of B-cell malignancies, the advent of immunotherapy, an escalation in funding for oncology research, the emergence of CAR-T cell therapies, increasing awareness about healthcare, and the growing field of personalized medicine.

The market for CD-19 antibodies is predicted to experience significant expansion in the coming years, with its value expected to reach “$2.64 billion by 2029”, witnessing a compound annual growth rate of 8.6%. This growth during the projected period can be due to factors including an increasing demand for cancer treatments aimed specifically at tumours, a surge in the acceptance of smart cell therapies, a growing incidence of blood cancer, extended accessibility to health care services in developing markets, and the advancement of next-generation immune therapies coupled with enhancement in bio-manufacturing technologies. The forecast period will also likely showcase trends such as progress in antibody-drug combinations, the evolution of bispecific antibodies, incorporation of AI into antibody design, advancements in cell-cell therapy platforms, the implementation of single-use bioreactors, the appearance of therapeutic treatments based on nanobodies, and the automation in the manufacturing of biological products.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21130&type=smp

Which Key Factors Are Fueling Growth In The CD-19 Antibody Market?

The CD-19 antibody market is anticipated to experience robust growth due to the increasing incidences of B-cell malignancies. B-cell malignancies comprise a variety of cancers that originate from irregular B lymphocytes and includes illnesses like B-cell lymphomas and leukemias. These conditions impact the immune system and can result in unchecked cell growth. The escalating occurrence of B-cell malignancies is connected to multiple factors such as an aging population, genetic predispositions, environmental exposure, lifestyle choices, improved diagnostics, and alterations in the immune system. The CD19 antibody is utilized to treat B-cell malignancies by selectively targeting the CD19 protein found on the surface of the malignant B cells. This specific targeting results in the eradication of these cells while preserving the healthy cells and bolstering the body’s immune defenses. For example, the American Cancer Society, a US-based non-profit organization, reported that 80,620 individuals in the USA were expected to be diagnosed with non-Hodgkin lymphoma in January 2024, and 20,240 individuals, including 44,590 males and 36,030 females, were projected to succumb to non-Hodgkin lymphoma. Thus, the increasing incidences of B-cell malignancies are fuelling the expansion of the CD-19 antibody market.

How Does The CD-19 Antibody Market Differ By Segment?

The cd-19 antibody market covered in this report is segmented –

1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types

2) By Type: Polyclonal, Monoclonal

3) By Route Of Administration: Intravenous, Subcutaneous

4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications

Subsegments:

1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma

2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL, Treatment-Naïve CLL

3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL

4) By Other Disease Types: Hairy Cell Leukemia, Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma

What New Opportunities Are Emerging From Trends In The CD-19 Antibody Market?

Leading firms in the CD-19 antibody market are directing their efforts towards technological advancements, such as genetically engineered autologous T-cell immunotherapy, to improve the effectiveness of cancer therapies, especially in terms of hematologic malignancies. The described therapy involves genetically modifying a patient’s own T cells to identify and combat cancer cells, these are then reintroduced to the patient’s body to boost the immune response against the disease. An example of this is Autolus Therapeutics plc, a biopharmaceutical firm based in the US, which announced in November 2024 that it had received U.S. FDA approval for AUCATZYL (obecabtagene autoleucel). This is used for the treatment of adult patients suffering from relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This method is designed to curtail excess T-cell activation, thus reducing toxicity and improving the longevity of the therapeutic cells. The treatment is administered in split-dose infusion on the first and tenth days, with dosage determined through a bone marrow assessment prior to treatment.

Who Are The Primary Market Leaders In The CD-19 Antibody Market?

Major companies operating in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/cd-19-antibody-global-market-report

Which Region Is Likely To Register The Fastest Growth In The CD-19 Antibody Market?

North America was the largest region in the CD-19 antibody market in 2024. The regions covered in the CD-19 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21130&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Is the Outlook for the Cephalosporin Market Heading Into 2029?#_x000D_

In recent years, the CD-19 antibody market has seen robust growth. It is projected to expand from a market value of $1.75 billion in 2024 to $1.89 billion in 2025, boasting a compound annual growth rate (CAGR) of 8.3%. This significant growth during the historical period can be credited to factors like the rising occurrence of B-cell malignancies, the advent of immunotherapy, an increase in investments for oncology research, the introduction of CAR-T cell therapies, increased healthcare awareness, and the growth of personalized medicine._x000D_

_x000D_

Anticipated robust growth is on the cards for the CD-19 antibody market, which is projected to balloon to “$2.64 billion in 2029 at a compounding annual growth rate (CAGR) of 8.6%. This growth spike during the predicted timeframe can be contributed to factors such as the escalating need for targeted therapies for cancer, widespread acceptance of intelligent cell treatments, increasing instances of hematologic malignancies, healthcare access widening in emerging markets, and enhancements in immunotherapies and biomanufacturing technologies. Important emerging trends for this foreseeable period include advancements in antibody-drug conjugates, cultivation of bispecific antibodies, incorporation of AI in the design of antibodies, refinements in platforms dealing with cell-cell therapy, the shift towards single-use bioreactors, the advent of nanobody-based therapeutic means, and the automation of biologics production._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21130&type=smp_x000D_

_x000D_

#Which Factors Are Pushing The Cephalosporin Market Forward?#_x000D_

An expected surge in infectious diseases incidents is forecasted to substantially boost the cephalosporin market’s expansion. Pathogenic microorganisms, such as bacteria, viruses, fungi, and parasites, cause infectious diseases by invading and multiplying, which can spread from person to person, causing diseases like tuberculosis, malaria, and flu. The rise in infectious diseases results in an increased demand for cephalosporin antibiotics, regularly employed to treat bacterial pathogen-induced infectious ailments due to their significant role in controlling and battling bacterial infections. In March 2023, for example, the US-based national public health body, the Centers for Disease Control and Prevention, reported 8,300 tuberculosis (TB) cases in the United States for the year 2022, marking an increase from 7,874 cases in 2021. Consequently, the escalating prevalence of infectious diseases is anticipated to fuel the growth of the cephalosporin market._x000D_

_x000D_

_x000D_

The cd-19 antibody market covered in this report is segmented – _x000D_

_x000D_

1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types_x000D_

2) By Type: Polyclonal, Monoclonal_x000D_

3) By Route Of Administration: Intravenous, Subcutaneous_x000D_

4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma _x000D_

2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL, Treatment-Naïve CLL _x000D_

3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL _x000D_

4) By Other Disease Types: Hairy Cell Leukemia, Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma_x000D_

_x000D_

#Which Emerging Trends And Strategic Shifts Are Shaping The Cephalosporin Market?#_x000D_

In the CD-19 antibody market, major industry players are concentrating on the development of innovative technology such as genetically engineered autologous T-cell immunotherapy, aimed at improving the effectiveness of cancer treatments, specifically for blood cancers. This advanced therapy involves modifying a patient’s T cells to recognize and eliminate cancer cells, which are then infused back into the patient’s body to fortify the immune response against the disease. In November 2024, Autolus Therapeutics plc, an American biopharmaceutical firm, received approval from the U.S. FDA for AUCATZYL (obecabtagene autoleucel), a treatment intended for adults suffering from B-cell precursor acute lymphoblastic leukemia (ALL) that has relapsed or become resistant to treatment. The therapeutic design is devised to manage T-cell activation and mitigate toxicity, thereby enhancing the life span of the therapeutic cells. Individual doses, split between days 1 and 10, are determined through a bone marrow assessment prior to treatment._x000D_

_x000D_

#Which Organizations Are Driving Progress In The Cephalosporin Industry?#_x000D_

Major companies operating in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc. _x000D_

_x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/cd-19-antibody-global-market-report_x000D_

_x000D_

#Which Region Is Expected To Experience The Highest Growth In The Cephalosporin Industry?#_x000D_

North America was the largest region in the CD-19 antibody market in 2024. The regions covered in the CD-19 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21130&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What is the Projected CAGR for the CD-19 Antibody Market Size from 2025 to 2034?#_x000D_

There has been a significant growth in the market size of the CD-19 antibody in the recent past. The value is expected to elevate from $1.75 billion in 2024 to a projection of $1.89 billion by 2025, exhibiting a compound annual growth rate (CAGR) of around 8.3%. This past expansion has been a result of various factors including a rise in B-cell malignancies, the advancement of immunotherapy, increase in the funding for oncology research, the development of CAR-T cell therapies, enhanced awareness in healthcare and finally, the growth of personalized medicine._x000D_

_x000D_

The market size of the CD-19 antibody is poised for substantial growth in the coming years, projected to reach $2.64 billion in 2029, expanding at a compound annual growth rate (CAGR) of 8.6%. Factors contributing to this growth in the forecasted period include the escalating demand for specialized cancer treatments, the increasing use of intelligent cell therapies, a growing number of hematologic malignancy cases, broader healthcare availability in emerging markets, and the advancement of next-generation immunotherapies and enhancements in biomanufacturing technologies. The forecast period also foresees important trends such as progress in antibody-drug conjugates, the creation of bispecific antibodies, the use of AI in creating antibodies, enhancements in cell-cell therapy platforms, the use of single-use bioreactors, the rise of nanobody-based treatments, and automation in the production of biologics._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21130&type=smp_x000D_

_x000D_

#Which Factors and External Forces Are Driving Demand in the CD-19 Antibody Market?#_x000D_

The escalating occurrence of B-cell malignancies is predicted to drive the advancement of the CD-19 antibody market in the future. B-cell malignancies encompass a range of cancers that stem from irregular B lymphocytes, such as B-cell lymphomas and leukemias. These conditions negatively impact the immune system and can result in unchecked cell proliferation. The increased incidence of B-cell malignancies is linked to a multitude of factors, including an ageing demographic, genetic predispositions, environmental influences, lifestyle choices, enhanced diagnostics, and modifications in the immune system. CD19 antibodies serve to combat B-cell malignancies by explicitly focusing on the CD19 protein found on malignant B cells. This results in the eradication of the harmful cells, while leaving healthy cells untouched, thereby enhancing the host’s immune response. For example, the American Cancer Society revealed that an approximate 80,620 individuals were projected to be diagnosed with non-Hodgkin lymphoma in the United States in January 2024. Around 20,240 people, with a breakdown of 44,590 males and 36,030 females, were projected to succumb to non-Hodgkin lymphoma. Therefore, the mounting rates of B-cell malignancies are fuelling the expansion of the CD-19 antibody market._x000D_

_x000D_

#Which Segments in the CD-19 Antibody Offer the Most Growth?#_x000D_

The cd-19 antibody market covered in this report is segmented – _x000D_

_x000D_

1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types_x000D_

2) By Type: Polyclonal, Monoclonal_x000D_

3) By Route Of Administration: Intravenous, Subcutaneous_x000D_

4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma _x000D_

2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL, Treatment-Naïve CLL _x000D_

3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL _x000D_

4) By Other Disease Types: Hairy Cell Leukemia, Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21130&type=smp_x000D_

_x000D_

#What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the CD-19 Antibody Market?# Market?#_x000D_

North America was the largest region in the CD-19 antibody market in 2024. The regions covered in the CD-19 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Which Cutting-Edge Market Trends Are Expected to Drive theCD-19 Antibody Market’s Growth?#_x000D_

Prominent firms in the CD-19 antibody market are concentrating their efforts on creating technological advancements, such as genetically engineered autologous T-cell immunotherapy. This technology aims to boost the effectiveness of cancer treatments, specifically those for blood-based cancers. The therapy involves genetically altering a patient’s own T cells so they are able to identify and combat cancer cells. These modified cells are then reintroduced into the patient’s body to amplify the immune response against the disease. As an example, in November 2024, Autolus Therapeutics PLC, an American biopharmaceutical corporation, declared that the U.S. FDA had given their approval for AUCATZYL (obecabtagene autoleucel), a treatment intended for adults dealing with relapsed or unresponsive B-cell precursor acute lymphoblastic leukemia (ALL). The aim of this design is to diminish excessive T-cell activation, thus curbing toxicity and prolonging the survival of the therapeutic cells. The therapy is given as a divided dose on the first and tenth days, with the dosage being customized based on a bone marrow examination prior to treatment._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/cd-19-antibody-global-market-report_x000D_

_x000D_

#What Are the Key Elements That Define the CD-19 Antibody Market?#_x000D_

CD19 antibody refers to a monoclonal antibody that specifically targets the CD19 protein, a cell surface marker found primarily on B cells. CD19 is critical in B cell development and is often overexpressed in B cell-related malignancies, such as certain leukemias and lymphomas. These antibodies are used in immunotherapy, including CAR-T cell therapy, to treat cancers by directing the immune system to attack CD19-expressing cells._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21130_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the CD-19 Antibody Market Grown from 2024 to 2025?

In recent times, the CD-19 antibody market has seen significant growth and this trend is expected to continue. Anticipated to rise from $1.75 billion in 2024 to $1.91 billion in 2025, the market will experience a compound annual growth rate (CAGR) of 9.3%. The substantial growth in the historical period is linked to several factors such as the increased incidence of B-cell malignancies, advancements in immunotherapy, a surge in funding for oncology research, emergence of CAR-T cell therapies, growing awareness about healthcare, and the broadening of personalized medicine.

What Growth Rate Is Anticipated for the CD-19 Antibody Market in the Coming Years?

Anticipations for the CD-19 antibody market forecast considerable expansion in the years to come. This sector is projected to increase to $2.70 billion in 2029 with a compound annual growth rate (CAGR) of 9.0%. Several variables can be credited for the expected growth, such as the burgeoning demand for specialized cancer treatments, escalating acceptance of smart cell therapies, the increasing occurrence of hematologic malignancies. Other factors include better healthcare accessibility in emerging markets, and the evolution of next-generation immunotherapies and enhancements in biomanufacturing technologies. Noteworthy trends for the forecast period encompass advancements in antibody-drug conjugation, the emergence of bispecific antibodies, the application of AI in antibody blueprint, advancements in cell therapy platforms, inclinations towards single-use bioreactors, the rise of nanobody-based treatments, and the integration of automation in biologics production.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21130&type=smp

Who Are the Leading Companies in the CD-19 Antibody Market?

Major companies operating in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.

What Are the Key Drivers of the CD-19 Antibody Market?

The escalating incidence of B-cell malignancies is set to drive the expansion of the CD-19 antibody market in the future. B-cell malignancies are a categorization of cancers that emerge from atypical B lymphocytes, encompassing conditions like B-cell lymphomas and leukemias, these affect the immune system and can lead to rampant cell growth. The escalating incidence of B-cell malignancies is credited to a range of reasons including an aging demographic, genetic causes, environmental contact, lifestyle, enhanced detection, and adjustments within the immune system. CD19 antibody assists in treating B-cell malignancies by zeroing in on the CD19 protein on the exterior of malignant B cells, triggering their dissolution while preserving healthy cells and amplifying the body’s immune response. For example, in January 2024, the American Cancer Society, a non-profit organization based in the US, declared that approximately 80,620 individuals were presumed to be diagnosed with non-Hodgkin lymphoma in the US, alongside 20,240 individuals, consisting of 44,590 males and 36,030 females, anticipated to pass away as a result of non-Hodgkin lymphoma. Hence, the escalating incidence of B-cell malignancies is steering the growth of the CD-19 antibody market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21130&type=smp

What Are the Key Market Segments in the CD-19 Antibody Industry?

The CD-19 antibody market covered in this report is segmented –

1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types

2) By Type: Polyclonal, Monoclonal

3) By Route Of Administration: Intravenous, Subcutaneous

4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications

Subsegments:

1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma

2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL, Treatment-Naïve CLL

3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL

4) By Other Disease Types: Hairy Cell Leukemia, Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma

What Are the Latest Trends in the CD-19 Antibody Market?

In the CD-19 antibody market, key players are devoting their efforts to technological advancements, including genetically engineered autologous T-cell immunotherapy, in order to improve the effectiveness of cancer treatments, specifically for blood cancers. This therapy involves modifying a patient’s own T cells genetically to recognize and destroy cancer cells, which are then reinserted into the patient’s body to boost the immune response against the disease. For example, Autolus Therapeutics plc, a US biotech firm, received U.S. FDA approval in November 2024 for AUCATZYL (obecabtagene autoleucel). This is intended for treating adults suffering from relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The goal of this approach is to lessen excessive T-cell activation, thus reducing toxicity and increasing the durability of the therapeutic cells. The therapy is given as two separate doses on the first and tenth day, with the doses tailored based on a bone marrow evaluation prior to treatment.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cd-19-antibody-global-market-report

What Are the Key Regional Markets in the CD-19 Antibody Industry?

North America was the largest region in the CD-19 antibody market in 2024. The regions covered in the CD-19 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21130

This Report Delivers Insight On:

1. How big is the cd-19 antibody market, and how is it changing globally?

2. Who are the major companies in the cd-19 antibody market, and how are they performing?

3. What are the key opportunities and risks in the cd-19 antibody market right now?

4. Which products or customer segments are growing the most in the cd-19 antibody market?

5. What factors are helping or slowing down the growth of the cd-19 antibody market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

How Fast Is The CD-19 Antibody Market Expected to Grow Between 2025 And 2029?

The market size for the CD-19 antibody has seen significant expansion in the past few years. The compound annual growth rate (CAGR) from 2024 to 2025 is projected at 9.3%, taking the market from a value of $1.75 billion to $1.91 billion. The factors contributing to this historic period of growth include a surge in B-cell malignancies, the rise of immunotherapy, increased funding for oncology research, the advent of CAR-T cell therapies, growing awareness in healthcare, and the broadening of personalized medicine.

In the coming years, the CD-19 antibody market size is projected to experience significant growth, swelling to a valuation of $2.70 billion in 2029 at a CAGR of 9.0%. This growth trajectory is linked to factors such as the rising need for targeted cancer treatments, increased use of smart cell therapies, growing incidence of hematologic malignancies, broader access to healthcare in growing markets, and the rise of next-generation immunotherapies bolstered by advancements in biomanufacturing technologies. The forecast period will likely see key trends like progress in antibody-drug conjugates, creation of bispecific antibodies, the use of AI in antibody design, enhancement of cell-cell therapy platforms, a shift towards single-use bioreactors, the advent of nanobody-based therapeutics, and increased automation in biologics production.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21130&type=smp

What Are the Core Market Drivers Propelling Growth in the CD-19 Antibody Industry?

The surge in B-cell malignancies is projected to stimulate expansion in the CD-19 antibody market. B-cell malignancies are a group of cancers arising from mutated B lymphocytes, encapsulating illnesses like B-cell lymphomas and leukemias, which influence the immune system and can induce unregulated cell proliferation. The growth in the incidence of B-cell malignancies can be accredited to several influences such as older population demographics, genetic determinants, environmental impacts, lifestyle factors, improved detection methods, and alterations in the immune system. The CD19 antibody aids in combating B-cell malignancies by specifically batch-marking the CD19 protein found on malignant B cells, resulting in their elimination while preserving healthy cells and augmenting the body’s immune defense. As an example, in January 2024, the American Cancer Society, a non-profit organization based in the U.S, predicted that about 80,620 individuals in the U.S would be identified with non-Hodgkin lymphoma, with 20,240 people, which includes 44,590 males and 36,030 females, projected to succumb to non-Hodgkin lymphoma. Therefore, the proliferating occurrence of B-cell malignancies is accelerating the expansion of the CD-19 antibody market.

How Is the CD-19 Antibody Market Segmented?

The CD-19 antibody market covered in this report is segmented –

1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types

2) By Type: Polyclonal, Monoclonal

3) By Route Of Administration: Intravenous, Subcutaneous

4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications

Subsegments:

1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma

2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL, Treatment-Naïve CLL

3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL

4) By Other Disease Types: Hairy Cell Leukemia, Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21130&type=smp

Which Regions Are Driving the Next Phase of the CD-19 Antibody Market Growth?

North America was the largest region in the CD-19 antibody market in 2024. The regions covered in the CD-19 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the CD-19 Antibody Industry?

Leading corporations in the CD-19 antibody market are prioritizing the creation of technological advancements such as genetically modified autologous T-cell immunotherapy. This centers on improving the effectiveness of cancer therapies, particularly for blood cancers. The process involves the genetic alteration of a patient’s own T cells to recognize and combat cancer cells. These cells are then reintroduced into the patient’s body to boost the immune response against the disorder. Autolus Therapeutics plc, a US biotech company, for example, declared in November 2024 that AUCATZYL (obecabtagene autoleucel), their treatment for adult patients with B-cell precursor acute lymphoblastic leukemia (ALL) that has relapsed or become unresponsive, had received U.S. FDA approval. This strategy seeks to curb excessive T-cell activation, therefore diminishing toxicity and promoting the longevity of therapeutic cells. The treatment involves a split-dose infusion on days 1 and 10, with doses tailored based on a bone marrow evaluation before treatment.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cd-19-antibody-global-market-report

How Is the CD-19 Antibody Market Defined and What Are Its Core Parameters?

CD19 antibody refers to a monoclonal antibody that specifically targets the CD19 protein, a cell surface marker found primarily on B cells. CD19 is critical in B cell development and is often overexpressed in B cell-related malignancies, such as certain leukemias and lymphomas. These antibodies are used in immunotherapy, including CAR-T cell therapy, to treat cancers by directing the immune system to attack CD19-expressing cells.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21130

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Industry-Specific Factors Are Fueling the Growth of theCD-19 Antibody Market?

The rising prevalence of B-cell malignancies is expected to propel the growth of the CD-19 antibody market. B-cell malignancies, including B-cell lymphomas and leukemias, are cancers originating from abnormal B lymphocytes. Factors such as aging, genetics, and environmental exposures contribute to the increasing incidence of these cancers. CD19 antibodies target and destroy malignant B-cells, improving treatment outcomes. For example, the American Cancer Society reported that in 2024, around 80,620 people in the U.S. were expected to be diagnosed with non-Hodgkin lymphoma. The rising prevalence of B-cell malignancies is thus driving the growth of the CD-19 antibody market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21130&type=smp

How Has the CD-19 Antibody Market Evolved in Recent Years, and What are the Growth Projections for the Forecast Period?

The CD-19 antibody market has experienced significant growth, projected to rise from $1.75 billion in 2024 to $1.91 billion in 2025, reflecting a CAGR of 9.3%. Growth in the past period can be attributed to the increasing prevalence of B-cell malignancies, the expansion of immunotherapy, rising oncology research funding, the emergence of CAR-T cell therapies, greater healthcare awareness, and the growth of personalized medicine.

The CD-19 antibody market is expected to experience strong growth, reaching $2.70 billion by 2029 at a CAGR of 9.0%. Growth factors include increasing demand for targeted cancer therapies, rising adoption of smart cell therapies, a growing prevalence of hematologic malignancies, expanding healthcare access in developing regions, and advancements in next-generation immunotherapies and biomanufacturing technologies. Major trends in the forecast period include progress in antibody-drug conjugates, the development of bispecific antibodies, AI-driven antibody design, innovations in cell therapy platforms, the adoption of single-use bioreactors, the rise of nanobody-based therapeutics, and automation in biologics manufacturing.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21130

What Key Market Trends and Innovations Are Shaping the Future of theCD-19 Antibody Industry?

In the CD-19 antibody market, companies are working on genetically modified autologous T-cell immunotherapy to enhance cancer treatment efficacy, especially for hematologic malignancies. For instance, in November 2024, Autolus Therapeutics plc, a U.S.-based biopharmaceutical company, announced FDA approval for AUCATZYL (obecabtagene autoleucel) to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This treatment involves modifying T-cells to attack cancer cells and minimizing toxicity while enhancing cell persistence.

Which Companies Are Leading the Charge in Expanding theCD-19 Antibody Market Growth?

Major companies operating in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/cd-19-antibody-global-market-report

How is the Global CD-19 Antibody Market Segemented?

The CD-19 antibody market covered in this report is segmented –

1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types

2) By Type: Polyclonal, Monoclonal

3) By Route Of Administration: Intravenous, Subcutaneous

4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications

Subsegments:

1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma

2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL, Treatment-Naïve CLL

3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL

4) By Other Disease Types: Hairy Cell Leukemia, Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=21130&type=smp

Which Geographics are Influencing the Growth of the CD-19 Antibody Market?

North America was the largest region in the CD-19 antibody market in 2024. The regions covered in the CD-19 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global CD-19 Antibody Market 2025, By The Business Research Company:

Zollinger-Ellison Syndrome Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/zollinger-ellison-syndrome-treatment-global-market-report

Acute Respiratory Distress Syndrome Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

Global Anesthesia And Respiratory Devices Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/anesthesia-and-respiratory-devices-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Industry-Specific Factors Are Fueling the Growth of theCD-19 Antibody Market?

The rising prevalence of B-cell malignancies is expected to propel the growth of the CD-19 antibody market. B-cell malignancies, including B-cell lymphomas and leukemias, are cancers originating from abnormal B lymphocytes. Factors such as aging, genetics, and environmental exposures contribute to the increasing incidence of these cancers. CD19 antibodies target and destroy malignant B-cells, improving treatment outcomes. For example, the American Cancer Society reported that in 2024, around 80,620 people in the U.S. were expected to be diagnosed with non-Hodgkin lymphoma. The rising prevalence of B-cell malignancies is thus driving the growth of the CD-19 antibody market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21130&type=smp

How Has the CD-19 Antibody Market Evolved in Recent Years, and What are the Growth Projections for the Forecast Period?

The CD-19 antibody market has experienced significant growth, projected to rise from $1.75 billion in 2024 to $1.91 billion in 2025, reflecting a CAGR of 9.3%. Growth in the past period can be attributed to the increasing prevalence of B-cell malignancies, the expansion of immunotherapy, rising oncology research funding, the emergence of CAR-T cell therapies, greater healthcare awareness, and the growth of personalized medicine.

The CD-19 antibody market is expected to experience strong growth, reaching $2.70 billion by 2029 at a CAGR of 9.0%. Growth factors include increasing demand for targeted cancer therapies, rising adoption of smart cell therapies, a growing prevalence of hematologic malignancies, expanding healthcare access in developing regions, and advancements in next-generation immunotherapies and biomanufacturing technologies. Major trends in the forecast period include progress in antibody-drug conjugates, the development of bispecific antibodies, AI-driven antibody design, innovations in cell therapy platforms, the adoption of single-use bioreactors, the rise of nanobody-based therapeutics, and automation in biologics manufacturing.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21130

What Key Market Trends and Innovations Are Shaping the Future of theCD-19 Antibody Industry?

In the CD-19 antibody market, companies are working on genetically modified autologous T-cell immunotherapy to enhance cancer treatment efficacy, especially for hematologic malignancies. For instance, in November 2024, Autolus Therapeutics plc, a U.S.-based biopharmaceutical company, announced FDA approval for AUCATZYL (obecabtagene autoleucel) to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This treatment involves modifying T-cells to attack cancer cells and minimizing toxicity while enhancing cell persistence.

Which Companies Are Leading the Charge in Expanding theCD-19 Antibody Market Growth?

Major companies operating in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/cd-19-antibody-global-market-report

How is the Global CD-19 Antibody Market Segemented?

The CD-19 antibody market covered in this report is segmented –

1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types

2) By Type: Polyclonal, Monoclonal

3) By Route Of Administration: Intravenous, Subcutaneous

4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications

Subsegments:

1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma

2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL, Treatment-Naïve CLL

3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL

4) By Other Disease Types: Hairy Cell Leukemia, Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=21130&type=smp

Which Geographics are Influencing the Growth of the CD-19 Antibody Market?

North America was the largest region in the CD-19 antibody market in 2024. The regions covered in the CD-19 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global CD-19 Antibody Market 2025, By The Business Research Company:

Zollinger-Ellison Syndrome Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/zollinger-ellison-syndrome-treatment-global-market-report

Acute Respiratory Distress Syndrome Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

Global Anesthesia And Respiratory Devices Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/anesthesia-and-respiratory-devices-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the cd-19 antibody market grown in recent years?

The market size for CD-19 antibodies has significantly expanded in the past few years. The market is projected to increase from $1.75 billion in 2024 to $1.91 billion in 2025, representing a compound annual growth rate (CAGR) of 9.3%. This impressive growth in the historical period can be associated with the escalation in B-cell malignancies cases, adoption of immunotherapy, surge in funding for oncology research, development of CAR-T cell therapies, heightened healthcare awareness, and the broadening scope of personalized medicine.

How is the cd-19 antibody market size expected to evolve during the forecast period?

Predictions indicate robust enlargement of the CD-19 antibody market in the upcoming years, with its value escalating to $2.70 billion in 2029, marking a compound annual growth rate (CAGR) of 9.0%. The surge during the projected period can be credited to rising demand for specialized cancer treatments, an upswing in the application of smart cell therapies, an increase in the incidence of hematologic malignancies, the broadening of healthcare reach in emerging markets, along with progression in next-gen immunotherapies and enhancements in biomanufacturing technologies. The upcoming period is set to witness trends such as advancement in antibody-drug conjugates, evolution of bispecific antibodies, the utilization of AI in antibody formation, enhancements in cell-cell therapy platforms, the uptake of single-use bioreactors, the arrival of nanobody-based treatments, and the introduction of automation in biopharmaceutical production.

Get your cd-19 antibody market report here!

https://www.thebusinessresearchcompany.com/report/cd-19-antibody-global-market-report

Which key drivers are propelling the cd-19 antibody market’s growth?

The increasing frequency of B-cell malignancies is projected to boost the expansion of the CD-19 antibody market. B-cell malignancies are a set of cancers that start from abnormal B lymphocytes, including diseases like B-cell lymphomas and leukemias, which harm the immune system and may result in uncontrolled cell growth. This growing occurrence is linked to a variety of factors such as aging population, genetic elements, environmental exposure, lifestyle choices, enhanced detection, and modifications in the immune system. The CD19 antibody works by specially targeting the CD19 protein on the surface of malignant B cells, leading to their eradication while preserving healthy cells and strengthening the body’s immune response. For example, in January 2024, the American Cancer Society, a US-based non-profit organization, estimated that approximately 80,620 individuals in the USA were diagnosed with non-Hodgkin lymphoma, and 20,240 people, including 44,590 men and 36,030 women, were projected to pass away due to non-Hodgkin lymphoma. Thus, the growing frequency of B-cell malignancies is fueling the expansion of the CD-19 antibody market.

What are the market segments in the cd-19 antibody industry?

The CD-19 antibody market covered in this report is segmented –

1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types

2) By Type: Polyclonal, Monoclonal

3) By Route Of Administration: Intravenous, Subcutaneous

4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications

Subsegments:

1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma

2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL, Treatment-Naïve CLL

3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL

4) By Other Disease Types: Hairy Cell Leukemia, Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21130&type=smp

Which leading companies are shaping the growth of the cd-19 antibody market?

Major companies operating in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.

What are the key trends shaping the future of the cd-19 antibody market?

Key players in the CD-19 antibody market are striving to introduce technologically advanced solutions, such as genetically engineered autologous T-cell immunotherapy, to improve the effectiveness of cancer therapies, particularly for blood-related cancers. Genetically engineered autologous T-cell therapy involves modifying the patient’s own T-cells to detect and combat cancer cells, before putting them back into the patient’s body to strengthen the immune response against the disease. For example, in November 2024, Autolus Therapeutics plc, an American biopharmaceutical firm, announced that the U.S. FDA had approved AUCATZYL (obecabtagene autoleucel) for the treatment of adult patients who had relapsed or had treatment-resistant B-cell precursor acute lymphoblastic leukemia (ALL). The goal of this treatment is to curb excessive T-cell activation, lessening toxicity and prolonged efficacy of the therapeutic cells. It is administered in split doses on the first and tenth day, with dosage personalized according to bone marrow evaluation before starting therapy.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21130

Which geographic areas are influencing the growth of the cd-19 antibody market?

North America was the largest region in the CD-19 antibody market in 2024. The regions covered in the CD-19 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Zollinger-Ellison Syndrome Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/zollinger-ellison-syndrome-treatment-global-market-report

Acute Respiratory Distress Syndrome Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

Global Anesthesia And Respiratory Devices Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/anesthesia-and-respiratory-devices-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Long-Term Projected Growth Rate for the CD-19 Antibody Market, and What Are the Key Drivers?

The market size for the CD-19 antibody has experienced significant growth in recent times. Figures project an increase from $1.75 billion in 2024 to $1.91 billion in 2025, translating to a compound annual growth rate (CAGR) of 9.3%. Contributing factors to the growth in this historical period include a rise in B-cell malignancies, surging popularity of immunotherapy, an upsurge in funding for oncology research, development of CAR-T cell therapies, heightened awareness of healthcare, and the advancement of personalized medicine.

In the coming years, the CD-19 antibody market is set to experience significant expansion. It’s projected to reach a valuation of $2.70 billion by 2029, with a CAGR of 9.0%. This expected growth in the forecast period is largely due to the increasing demand for specialized cancer treatments, the rising adoption of intelligent cell therapies, the growing occurrence of blood cancers, the widening access to healthcare in burgeoning markets, and advancements in next-generation immunotherapies and biomanufacturing technologies. Looking ahead, the forecast period is likely to see the progression of antibody-drug conjugates, the creation of bispecific antibodies, the application of AI in antibody design, advancements in cell-to-cell therapy platforms, the use of single-use bioreactors, the introduction of nanobody-based therapeutics, and the automation of biologics manufacturing processes.

What Drivers Are Shaping the Growth of the CD-19 Antibody Market?

B-cell malignancies are becoming increasingly prevalent, which is anticipated to spur the expansion of the CD-19 antibody market. B-cell malignancies are a category of cancers that arise from abnormal B lymphocytes and include conditions like B-cell lymphomas and leukemias. These conditions affect the immune system and can result in uncontrolled cellular growth. Factors like aging population, genetic predisposition, environmental factors, lifestyle choices, enhanced detection methods, and immune system alterations have been associated with the escalating prevalence of B-cell malignancies. CD19 antibody serves as a treatment for B-cell malignancies by specifically attacking the CD19 protein located on the surface of malignant B cells. This action not only destroys the malignant cells but also spares the healthy ones, thereby boosting the body’s immune response. For example, the American Cancer Society stated that in January 2024 in the USA, approximately 80,620 individuals were diagnosed with non-Hodgkin lymphoma, while it’s estimated that 20,240 individuals, comprising 44,590 males and 36,020 females, will succumb to the disease. Hence, the escalating prevalence of B-cell malignancies is fueling the growth of the CD-19 antibody market.

Get Your Free Sample of the Global CD-19 Antibody Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=21130&type=smp

Which Companies Are Leading the Charge in Expanding the CD-19 Antibody Market?

Major companies operating in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.

What New Trends Are Reshaping the CD-19 Antibody Market and Its Opportunities?

Leading firms in the CD-19 antibody market are prioritizing the creation of technological advancements including genetically modified autologous T-cell immunotherapy to improve the effectiveness of cancer therapies, especially in the context of blood cancers. This therapy involves genetically modifying a patient’s own T cells to identify and target cancerous cells, and then reintroducing these cells to strengthen the immune reaction towards the illness. For example, in November 2024, Autolus Therapeutics plc, a biopharmaceutical company based in the US, publicized its FDA approval for AUCATZYL (obecabtagene autoleucel), a solution for adult patients suffering from relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia (ALL). This groundbreaking method is designed to temper excessive T-cell activation, reducing toxicity while simultaneously boosting the longevity of curative cells. Accordingly, the treatment is provided through a split-dose infusion on the first and tenth days, with the precise dosage determined by a preceding assessment of the bone marrow.

Get Instant Access to the Global CD-19 Antibody Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/cd-19-antibody-global-market-report

What Major Market Segments Define the Scope and Growth of the CD-19 Antibody Market?

The CD-19 antibody market covered in this report is segmented –

1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types

2) By Type: Polyclonal, Monoclonal

3) By Route Of Administration: Intravenous, Subcutaneous

4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications

Subsegments:

1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma

2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL, Treatment-Naïve CLL

3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL

4) By Other Disease Types: Hairy Cell Leukemia, Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma

What Are the Top Regions Fueling Growth in the CD-19 Antibody Market?

North America was the largest region in the CD-19 antibody market in 2024. The regions covered in the CD-19 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the CD-19 Antibody Market Defined Across Different Regions?

CD19 antibody refers to a monoclonal antibody that specifically targets the CD19 protein, a cell surface marker found primarily on B cells. CD19 is critical in B cell development and is often overexpressed in B cell-related malignancies, such as certain leukemias and lymphomas. These antibodies are used in immunotherapy, including CAR-T cell therapy, to treat cancers by directing the immune system to attack CD19-expressing cells.

Browse Through More Similar Reports By The Business Research Company:

Zollinger-Ellison Syndrome Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/zollinger-ellison-syndrome-treatment-global-market-report

Acute Respiratory Distress Syndrome Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

Global Anesthesia And Respiratory Devices Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/anesthesia-and-respiratory-devices-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: